Bristol Myers Squibb has received approval from the European Commission for the subcutaneous formulation of Opdivo® (nivolumab) for use across multiple solid tumor indications. This makes Opdivo the first and only PD-1 inhibitor approved for subcutaneous administration in the EU. The approval follows results from the Phase 3 CheckMate -67T clinical trial, which demonstrated the noninferiority of the subcutaneous version compared to its intravenous counterpart. The decision is applicable in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. This new formulation offers a quicker, 3- to 5-minute injection, enhancing the patient experience while maintaining consistent efficacy and safety.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。